Raising the standard for viral monitoring and management
The quantitative adenovirus test (UC-DGN-ADVTM) accurately detects and monitors viral load of human Adenovirus (hADV) in immunocompromised and transplant patients. This real-time PCR test is designed to use in conjunction with the cobas omni Utility Channel on the cobas® 6800/8800 Systems in countries accepting the CE mark.
With the addition of this test, Roche’s transplant menu now allows comprehensive testing for Cytomegalovirus, Epstein-Barr virus, BK virus and human Adenovirus on the consolidated cobas® 6800/8800 Systems with an automated and simplified workflow.
Standardization – Results traceable to the WHO International standard for adenovirus (NIBSC code: 16/324) and reporting in IU/mL, for improved result harmonization in testing results across hospital institutions
Automation: Specifically designed and optimized for use on the cobas® 6800/8800 Systems, enabling menu testing consolidation and sample to result automation
Simplicity & efficiency: Minimizes variability and complexity in testing, offering an alternative to lab-developed tests (LDTs), reducing workload and alleviating risk of error for laboratories
Adenoviruses are important causes of infections and complications in both stem cell transplant and solid organ transplant patients and has been associated with a range of clinical syndromes.1 Adenovirus infections can spread through a cough or a sneeze, direct conjunctival inoculation, fecal-oral spread, or exposure to infected tissue or blood.2 After primary infection, the virus can remain latent for long periods of time. In immunocompromised and transplant individuals, especially in children, the latent virus can be reactivated and can be responsible for disseminated disease and graft loss, leading to high morbidity and mortality.3 Early intervention is required for making informed clinical decisions.
This test is intended for use as an aid in the diagnosis of human ADV infections and for monitoring ADV DNA levels such as in transplanted and immunocompromised patients. The results from UC-DGN-ADV™ must be interpreted within the context of all relevant clinical and laboratory findings.
Florescu et al. Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. The J of Clinical and Translational Research. 2019. https://doi.org/10.1111/ctr.13527
Kanakry JA, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016; Apr 21;127(16):2007-17
Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441–462. doi:10.1128/CMR.00116-13
UC-DGN-ADVTM is a trademark of Diagenode sa. Exclusively distributed worldwide by Roche Diagnostics GmbH